pharmacogenomics – Medxy AI

Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized Therapy

By MedXY 08/25/2026

A study reveals a higher prevalence of rapid CYP2C19 metabolizer phenotypes in GERD patients undergoing surgery versus medical therapy, supporting tailored proton pump inhibitor dosing and timely surgical referral.

Anesthesiology news Orthopedics

Precision Medicine Fails to Improve Postoperative Pain: Insights from the CYP2D6-Guided Opioid Trial

By MedXY 02/23/2026

A randomized clinical trial demonstrates that while CYP2D6 genotyping significantly shifts opioid prescribing patterns for poor and intermediate metabolizers, it does not improve pain control or reduce opioid consumption within the context of modern multimodal postoperative care.

news Psychiatry

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial

By MedXY 11/14/2025

In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), with acceptable tolerability.